July 08, 2019
1 min read

Phase 3 data supports lumateperone for bipolar depression

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Intra-Cellular Therapies, Inc. announced positive results from a phase 3 clinical trial evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder, according to a press release.

In Study 404, lumateperone improved depressive symptoms compared with placebo as measured by change in MADRS total score (least squares mean difference = 4.6 points; P < .001) as well as improved symptom severity as measured by change in Clinical Global Impression Scale for Bipolar for Severity of Illness total score (P < .001).

In another trial (Study 401), lumateperone did not met the primary endpoint of statistical separation from placebo; however, lumateperone 42 mg and 28 mg reduced depressive symptoms by 20.7 and 18.9 points on the MADRS total score compared with 19.7 points on placebo.

Lumateperone had a favorable safety profile and was generally well-tolerated in both trials, according to the release.

“We consider today’s positive results to be a significant milestone in our bipolar depression program. The distinct pharmacological profile of lumateperone and positive clinical results in schizophrenia and bipolar depression further support the potential for benefits in a broad range of neuropsychiatric conditions, including major depressive disorder,” Sharon Mates, PhD, chairman and CEO of Intra-Cellular Therapies, said in the release. “It is an exciting time at ITCI as we prepare for the launch of lumateperone for the treatment of schizophreniav, pending FDA approval.”